# Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics, today reported financial results for the first quarter of 2026.

*biotech · news · 2026-05-07 · City A.M.*

## Key points

- Roche's prasinezumab showed a sustained two-year delay in Parkinson's progression over five years in OLE studies.
- Novo Nordisk's coramitug received FDA Fast Track designation for ATTR-CM and triggered a $50 million payment to Prothena.
- Prothena's Q1 2026 net income was $32.7 million versus a $60.2 million loss in Q1 2025.
- Prothena lowered 2026 net cash burn guidance to $18–23 million, citing milestone revenue and spending reductions.
- Prothena may receive a $55 million milestone from Bristol Myers Squibb for PRX019 by year-end 2026.

**Companies:** Roche, Novo Nordisk, Bristol Myers Squibb, Prothena Corporation
**Countries:** United States

[Read the full story on City A.M.](https://www.cityam.com/prothena-reports-first-quarter-2026-financial-results-and-business-highlights/)

---

Canonical: https://newsio.io/n/2f7a12b2-c7b7-4f49-964c-8268a4cd74f5/prothena-corporation-plc-nasdaqprta-a-late-stage-clinical-biotechnology-company
Summarized by Newsio from City A.M.. https://newsio.io/how-it-works